Visica 2™
Cryoablation System

Fast, minimally invasive treatment

The Visica Treatment System, first used in 2000, has been proven safe and effective with thousands of fibroadenoma treatments completed. Patient and physician satisfaction is excellent, and the ease of in-office use has made Visica cryoablation the treatment of choice for many leading physicians.

Visica cryoablation treatment offers many advantages that are not offered through surgical lump removal. Click here to download the "Key Visica Patient Benefits Brochure."

FDA clearance

The FDA cleared The Visica Treatment System in 2001 as a minimally invasive and cost-effective alternative to surgical treatment of fibroadenoma. The system uses cryotechnology ICE Probes to deliver therapeutic freezing temperatures to targeted tissue to ablate or localize the fibroadenoma in a ball of ice. Ultrasound provides accurate guidance and confirms that the ice ball has fully engulfed and completely destroyed the fibroadenoma without affecting surrounding tissue.

Learn More

The entire procedure can be performed in-office in 10-30 minutes using local anesthesia.
Patients and physicians alike report high levels of satisfaction and excellent cosmetic results.
In over 2,000 procedures, not a single regrowth has been reported.

Patient profile

Patients who meet the following criteria may be considered good candidates for Visica 2 Treatment if they:

Have a histologically confirmed fibroadenoma 4 cm diameter
Desire a permanent, minimally invasive solution
Are fully aware of the healing and resorption process
Concerned with cosmetic outcomes

Sanarus' cryoablation produces this		Other procedures produce this



One month after treatment

The Visica 2^™ cryoablation treatment procedure



Fig. 1: The breast is prepared and a local anesthesia is given.		Fig. 2: Ultrasound imaging is used to locate the biopsy-proven fibroadenoma.



Fig. 3: A 3 mm incision (about 1/8 inch) is made in a cosmetically and technically appropriate location.		Fig. 4: Using ultrasound guidance, a 12G Visica cryoprobe with 3-point trocar tip is positioned in the center of the tumor.



Fig. 5: If the tumor is close to the skin, a protective layer of sterile saline is injected between the skin and the tumor.		Fig. 6: The Visica 2 treatment cycle is activated and an ice ball forms around the tumor. The freezing temperatures destroy the tumor tissue.



Fig. 7: The needle is removed from the breast and a sterile bandage is placed on the incision site. Over the next 3-12 months (depending on the size of the lesion), the body absorbs the destroyed tumor cells.